{"id":692348,"date":"2022-10-05T08:20:03","date_gmt":"2022-10-05T12:20:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/"},"modified":"2022-10-05T08:20:03","modified_gmt":"2022-10-05T12:20:03","slug":"medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/","title":{"rendered":"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO\u00a0and\u00a0HOUSTON, Oct.  05, 2022  (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp.\u00a0(\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37<sup>th<\/sup> Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 \u2013 12, 2022.<\/p>\n<p align=\"justify\">Both abstracts will be published by SITC at 8:00 a.m. ET on November 7, 2022. Additional details on the abstracts and corresponding poster presentations are shown below.<\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong>Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting \u2018Beta-only\u2019 IL2 Agonist<br \/><strong>Abstract Number: <\/strong>743<br \/><strong>Poster Presentation Date and Time: <\/strong>November 10, 2022, from 9:00 a.m. \u2013 9:00 p.m. ET<br \/><strong>Poster Session Location: <\/strong>Boston Convention and Exhibition Center, Hall C<\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong>Interim Single-agent Safety and Anti-tumor Activity from Dose Escalation Phase of ABILITY Study on MDNA11, a Long-acting Beta-only IL-2 Agonist<br \/><strong>Abstract Number: <\/strong>744<br \/><strong>Poster Presentation Date and Time: <\/strong>November 11, 2022, from 9:00 a.m. \u2013 8:30 p.m. ET<br \/><strong>Poster Session Location: <\/strong>Boston Convention and Exhibition Center, Hall C<\/p>\n<p align=\"justify\">\n        <strong>About Medicenna <\/strong><br \/>\n        <br \/>Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna&#8217;s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna\u2019s early-stage BiSKITs\u2122 program, (<strong>Bi<\/strong>functional\u00a0<strong>S<\/strong>uper<strong>K<\/strong>ine<strong>\u00a0I<\/strong>mmuno<strong>T<\/strong>herapie<strong>s<\/strong>)\u00a0is designed to enhance the ability of Superkines to treat immunologically \u201ccold\u201d tumors. Medicenna&#8217;s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA\/EMA, respectively.<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MGRmMzdkNWUtODFiMy00MDNhLWJiMzEtOGEzYjBmNjY5OGRlLTExMzQwNTI=\/tiny\/Medicenna-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Further Information\r\n\r\nFor further information about the Company please contact:\r\n\r\nElizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com\r\n\r\nInvestor Contact\r\n\r\nFor more investor information, please contact:\r\n\r\nDan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO\u00a0and\u00a0HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp.\u00a0(\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 \u2013 12, 2022. Both abstracts will be published by SITC at 8:00 a.m. ET on November 7, 2022. Additional details on the abstracts and corresponding poster presentations are shown below. Title: Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting \u2018Beta-only\u2019 IL2 AgonistAbstract Number: 743Poster Presentation Date and Time: November 10, 2022, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692348","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO\u00a0and\u00a0HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp.\u00a0(\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 \u2013 12, 2022. Both abstracts will be published by SITC at 8:00 a.m. ET on November 7, 2022. Additional details on the abstracts and corresponding poster presentations are shown below. Title: Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting \u2018Beta-only\u2019 IL2 AgonistAbstract Number: 743Poster Presentation Date and Time: November 10, 2022, &hellip; Continue reading &quot;Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T12:20:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting\",\"datePublished\":\"2022-10-05T12:20:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/\"},\"wordCount\":317,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/\",\"name\":\"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=\",\"datePublished\":\"2022-10-05T12:20:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting - Market Newsdesk","og_description":"TORONTO\u00a0and\u00a0HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp.\u00a0(\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 \u2013 12, 2022. Both abstracts will be published by SITC at 8:00 a.m. ET on November 7, 2022. Additional details on the abstracts and corresponding poster presentations are shown below. Title: Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting \u2018Beta-only\u2019 IL2 AgonistAbstract Number: 743Poster Presentation Date and Time: November 10, 2022, &hellip; Continue reading \"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T12:20:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting","datePublished":"2022-10-05T12:20:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/"},"wordCount":317,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/","name":"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=","datePublished":"2022-10-05T12:20:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODk2MyM1MTg3MzE3IzIxMjI0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692348"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692348\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}